Inari Medical (NASDAQ:NARI – Get Free Report) is set to release its earnings data after the market closes on Monday, October 28th. Analysts expect Inari Medical to post earnings of ($0.11) per share for the quarter. Inari Medical has set its FY 2024 guidance at EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.
Inari Medical (NASDAQ:NARI – Get Free Report) last announced its earnings results on Tuesday, July 30th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.25). The company had revenue of $145.82 million for the quarter, compared to the consensus estimate of $143.96 million. Inari Medical had a negative return on equity of 7.51% and a negative net margin of 10.42%. On average, analysts expect Inari Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Inari Medical Stock Up 1.7 %
NASDAQ NARI opened at $44.23 on Monday. The company has a market capitalization of $2.57 billion, a P/E ratio of -107.88 and a beta of 1.00. Inari Medical has a 12-month low of $36.73 and a 12-month high of $67.13. The firm has a 50-day moving average price of $44.11 and a two-hundred day moving average price of $45.85.
Insider Buying and Selling
Analysts Set New Price Targets
A number of research firms have issued reports on NARI. Leerink Partnrs raised shares of Inari Medical to a “hold” rating in a report on Tuesday, September 3rd. Stifel Nicolaus assumed coverage on shares of Inari Medical in a research report on Tuesday, September 17th. They issued a “hold” rating and a $50.00 target price for the company. Needham & Company LLC restated a “hold” rating on shares of Inari Medical in a research report on Wednesday, October 9th. Robert W. Baird dropped their target price on shares of Inari Medical from $65.00 to $63.00 and set an “outperform” rating for the company in a research report on Wednesday, July 31st. Finally, Leerink Partners assumed coverage on shares of Inari Medical in a research report on Tuesday, September 3rd. They issued a “market perform” rating and a $47.00 target price for the company. Six investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $57.44.
Check Out Our Latest Stock Report on Inari Medical
About Inari Medical
Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.
Read More
- Five stocks we like better than Inari Medical
- Insider Trading – What You Need to Know
- Is Spotify Stock Poised to Soar? Options Traders Think So
- What Are Dividend Contenders? Investing in Dividend Contenders
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- What is the S&P 500 and How It is Distinct from Other Indexes
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.